185 related articles for article (PubMed ID: 22234627)
41. A phase I/II prospective, single arm trial of gefitinib, trastuzumab, and docetaxel in patients with stage IV HER-2 positive metastatic breast cancer.
Somlo G; Martel CL; Lau SK; Frankel P; Ruel C; Gu L; Hurria A; Chung C; Luu T; Morgan R; Leong L; Koczywas M; McNamara M; Russell CA; Kane SE
Breast Cancer Res Treat; 2012 Feb; 131(3):899-906. PubMed ID: 22042372
[TBL] [Abstract][Full Text] [Related]
42. Tucatinib with capecitabine and trastuzumab in advanced HER2-positive metastatic breast cancer with and without brain metastases: a non-randomised, open-label, phase 1b study.
Murthy R; Borges VF; Conlin A; Chaves J; Chamberlain M; Gray T; Vo A; Hamilton E
Lancet Oncol; 2018 Jul; 19(7):880-888. PubMed ID: 29804905
[TBL] [Abstract][Full Text] [Related]
43. Trastuzumab plus docetaxel in HER-2/neu-positive prostate carcinoma: final results from the California Cancer Consortium Screening and Phase II Trial.
Lara PN; Chee KG; Longmate J; Ruel C; Meyers FJ; Gray CR; Edwards RG; Gumerlock PH; Twardowski P; Doroshow JH; Gandara DR
Cancer; 2004 May; 100(10):2125-31. PubMed ID: 15139054
[TBL] [Abstract][Full Text] [Related]
44. Phase II study of bevacizumab in combination with trastuzumab and capecitabine as first-line treatment for HER-2-positive locally recurrent or metastatic breast cancer.
Martín M; Makhson A; Gligorov J; Lichinitser M; Lluch A; Semiglazov V; Scotto N; Mitchell L; Tjulandin S
Oncologist; 2012; 17(4):469-75. PubMed ID: 22467666
[TBL] [Abstract][Full Text] [Related]
45. Quantitation of p95HER2 in paraffin sections by using a p95-specific antibody and correlation with outcome in a cohort of trastuzumab-treated breast cancer patients.
Sperinde J; Jin X; Banerjee J; Penuel E; Saha A; Diedrich G; Huang W; Leitzel K; Weidler J; Ali SM; Fuchs EM; Singer CF; Köstler WJ; Bates M; Parry G; Winslow J; Lipton A
Clin Cancer Res; 2010 Aug; 16(16):4226-35. PubMed ID: 20664024
[TBL] [Abstract][Full Text] [Related]
46. Two histopathologically different diseases: hormone receptor-positive and hormone receptor-negative tumors in HER2-positive breast cancer.
Lee HJ; Park IA; Park SY; Seo AN; Lim B; Chai Y; Song IH; Kim NE; Kim JY; Yu JH; Ahn JH; Gong G
Breast Cancer Res Treat; 2014 Jun; 145(3):615-23. PubMed ID: 24820412
[TBL] [Abstract][Full Text] [Related]
47. Fluorescence in situ hybridization (FISH) for detection of HER-2/neu amplification in breast cancer: a multicenter portability study.
Persons DL; Bui MM; Lowery MC; Mark HF; Yung JF; Birkmeier JM; Wong EY; Yang SJ; Masood S
Ann Clin Lab Sci; 2000 Jan; 30(1):41-8. PubMed ID: 10678582
[TBL] [Abstract][Full Text] [Related]
48. Phase II Study of Weekly Paclitaxel with Trastuzumab and Pertuzumab in Patients with Human Epidermal Growth Receptor 2 Overexpressing Metastatic Breast Cancer: 5-Year Follow-up.
Wang R; Smyth LM; Iyengar N; Chandarlapaty S; Modi S; Jochelson M; Patil S; Norton L; Hudis CA; Dang CT
Oncologist; 2019 Aug; 24(8):e646-e652. PubMed ID: 30602614
[TBL] [Abstract][Full Text] [Related]
49. Her-2/neu status in breast cancer metastases to the central nervous system.
Lear-Kaul KC; Yoon HR; Kleinschmidt-DeMasters BK; McGavran L; Singh M
Arch Pathol Lab Med; 2003 Nov; 127(11):1451-7. PubMed ID: 14567724
[TBL] [Abstract][Full Text] [Related]
50. Isolated central nervous system metastases in patients with HER2-overexpressing advanced breast cancer treated with first-line trastuzumab-based therapy.
Burstein HJ; Lieberman G; Slamon DJ; Winer EP; Klein P
Ann Oncol; 2005 Nov; 16(11):1772-7. PubMed ID: 16150805
[TBL] [Abstract][Full Text] [Related]
51. Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors.
Niikura N; Liu J; Hayashi N; Mittendorf EA; Gong Y; Palla SL; Tokuda Y; Gonzalez-Angulo AM; Hortobagyi GN; Ueno NT
J Clin Oncol; 2012 Feb; 30(6):593-9. PubMed ID: 22124109
[TBL] [Abstract][Full Text] [Related]
52. HER2/CEP17 Ratios and Clinical Outcome in HER2-Positive Early Breast Cancer Undergoing Trastuzumab-Containing Therapy.
Stocker A; Hilbers ML; Gauthier C; Grogg J; Kullak-Ublick GA; Seifert B; Varga Z; Trojan A
PLoS One; 2016; 11(7):e0159176. PubMed ID: 27463363
[TBL] [Abstract][Full Text] [Related]
53. Simultaneous fluorescence immunophenotyping and Her-2/neu genotyping (FICTION) in breast carcinoma candidates to target therapy.
Gatta LB; Incardona P; Cadei M; Grigolato P; Simoncelli S; Balzarini P
Appl Immunohistochem Mol Morphol; 2012 Jul; 20(4):413-20. PubMed ID: 22417857
[TBL] [Abstract][Full Text] [Related]
54. Monosomy 17 in potentially curable HER2-amplified breast cancer: prognostic and predictive impact.
Page DB; Wen H; Brogi E; Dure D; Ross D; Spinelli KJ; Patil S; Norton L; Hudis C; McArthur HL
Breast Cancer Res Treat; 2018 Jan; 167(2):547-554. PubMed ID: 28986743
[TBL] [Abstract][Full Text] [Related]
55. HER-2 protein concentrations in breast cancer cells increase before immunohistochemical and fluorescence in situ hybridization analysis turn positive.
Olsen DA; Østergaard B; Bokmand S; Wamberg PA; Jakobsen EH; Brandslund I
Clin Chem Lab Med; 2007; 45(2):177-82. PubMed ID: 17311504
[TBL] [Abstract][Full Text] [Related]
56. Her-2 overexpression increases the metastatic outgrowth of breast cancer cells in the brain.
Palmieri D; Bronder JL; Herring JM; Yoneda T; Weil RJ; Stark AM; Kurek R; Vega-Valle E; Feigenbaum L; Halverson D; Vortmeyer AO; Steinberg SM; Aldape K; Steeg PS
Cancer Res; 2007 May; 67(9):4190-8. PubMed ID: 17483330
[TBL] [Abstract][Full Text] [Related]
57. HER-2/neu expression in primary and metastatic breast cancer.
Lower EE; Glass E; Blau R; Harman S
Breast Cancer Res Treat; 2009 Jan; 113(2):301-6. PubMed ID: 18273700
[TBL] [Abstract][Full Text] [Related]
58. Comparison of immunohistochemical and fluorescence in situ hybridization assessment for HER-2/neu status in Taiwanese breast cancer patients.
Kuo SJ; Wang BB; Chang CS; Chen TH; Yeh KT; Lee DJ; Yin PL; Chen M
Taiwan J Obstet Gynecol; 2007 Jun; 46(2):146-51. PubMed ID: 17638622
[TBL] [Abstract][Full Text] [Related]
59. Brain metastases from breast cancer: prognostic significance of HER-2 overexpression, effect of trastuzumab and cause of death.
Le Scodan R; Jouanneau L; Massard C; Gutierrez M; Kirova Y; Cherel P; Gachet J; Labib A; Mouret-Fourme E
BMC Cancer; 2011 Sep; 11():395. PubMed ID: 21929800
[TBL] [Abstract][Full Text] [Related]
60. Integrating molecular mechanisms and clinical evidence in the management of trastuzumab resistant or refractory HER-2⁺ metastatic breast cancer.
Wong H; Leung R; Kwong A; Chiu J; Liang R; Swanton C; Yau T
Oncologist; 2011; 16(11):1535-46. PubMed ID: 22020213
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]